Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. (Q46132299)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

0 references

0 references

0 references

non-alcoholic steatohepatitis

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

A Mallat

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 December 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

published in

Diabetes and Metabolism

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

680-684

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

6 Pt 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Non-alcoholic steatohepatitis: from cell biology to clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

The endocannabinoid system as an emerging target of pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Targeting the endocannabinoid system: to enhance or reduce?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

CB2 receptors as new therapeutic targets for liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Rimonabant in rats with a metabolic syndrome: good news after the depression.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Endocannabinoids and the control of energy homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Hepatic fibrosis: molecular mechanisms and drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Influence of cannabis use on severity of hepatitis C disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Obesity, Inflammation, and Insulin Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Inflammation and metabolic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

Cannabinoid-based drugs as anti-inflammatory therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974604-4

7 January 2021

10.1016/S1262-3636(08)74604-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19195630%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference